Costs of the management of hemophilia A with inhibitors in Spain

INTRODUCTION: Emicizumab is a first-in-class monoclonal antibody, recently authorized for the treatment of hemophilia A with inhibitors. This study aims to estimate the direct and indirect costs of the management of hemophilia A with inhibitors, in adult and pediatric patients, including the prophyl...

Descripción completa

Detalles Bibliográficos
Autores principales: Bonanad, Santiago, Álvarez, María Teresa, Núñez, Ramiro, Poveda, José Luis, Gil, Beatriz, Ruíz-Beato, Elena, Durán, Ana, Ivanova, Yoana, Pérez-Román, Inés, González-Domínguez, Almudena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AboutScience 2021
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9616192/
https://www.ncbi.nlm.nih.gov/pubmed/36627877
http://dx.doi.org/10.33393/grhta.2021.2234

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9616192/
https://www.ncbi.nlm.nih.gov/pubmed/36627877
http://dx.doi.org/10.33393/grhta.2021.2234

Ejemplares similares